How Patient Journey Analytics Improves Drug Commercialization
A drug's clinical trial data tells you how it performs under ideal conditions. It doesn't tell you where your patients actually are, why they're taking three years to get diagnosed, which physicians a ...
Why Most RWE Fails Payer Scrutiny (and What Actually Passes)
Real-world evidence is no longer optional in market access discussions. Payers expect it. HTA bodies ask for it. Internal teams invest heavily in generating it. And yet, a quiet reality persists: most ...
Beyond the Drug: Why Ecosystem Based Commercial Models Are Becoming Critical in Rare Diseases
The quiet truth about rare disease medicines is that a brilliant molecule or a one-time gene therapy is only the opening act. Getting the drug from a lab bench miracle into durable, equitable patient ...
From Evidence to Impact: How Thelansis Accelerated a Rare Disease Submission
Introduction: In recent years, the healthcare landscape has evolved toward an evidence-based, patient-centric architecture. Although conventional clinical trials remain the gold standard, they do not ...